CAD                                                  sarcoma(130)
 _________________________________________________________________
  cytoxan......... 500 mg/sqm IV day 1.
  adriamycin...... 60 mg/sqm IV day 2.
  dacarbazine..... 400 mg/sqm IV days 1 and 2.
  FREQUENCY....... Repeat cycle every 21 days.


  reference...
    Antman KH.  Blum RH.  Wilson RE.  Corson JM.  Greenberger JS.  
    Amato DA.  Canellos GP.  Frei E 3d. Survival of patients with 
    localized high-grade soft tissue sarcoma with multimodality 
    therapy. A matched control study. Cancer.  51(3):396-401, 1983 
    Feb 1. 
  abstract...
    Ten of 16 consecutive patients (63%) with Stages III-IVA soft 
    tissue sarcoma presenting between 1975 and 1978 and treated 
    with surgery, radiotherapy and adjuvant chemotherapy have 
    remained disease-free with a median follow-up of three years 
    (range, 28-68 months). Survival at three years was 86%. 
    However, in the American Joint Committee (AJC) soft tissue 
    sarcoma staging system published in 1977, Grade 3 soft tissue 
    sarcomas were associated with a three-year survival of 35% and 
    almost 90% of the patients destined to fail did so within 
    three years of diagnosis (8). To determine if the observed 
    improvement in survival resulted merely from lesions with 
    favorable prognostic determinants at diagnosis, study patients 
    were matched for stage, histologic type and location of the 
    primary lesion with controls generated from these 1215 
    carefully reviewed sarcoma patients collected from the data 
    base of the Task Force on Soft Tissue Sarcomas of the AJC. 
    Only control cases whose histology had been reviewed and who 
    had been treated with surgery (with or without radiotherapy) 
    were included in the analysis. Cases survived significantly 
    longer than controls at three years (p less than 0.001) and, 
    in fact, disease-free survival of cases (63%) was superior to 
    overall survival of controls (27%) (p less than 0.01). Our 
    data support the conclusion that patients with high-grade soft 
    tissue sarcoma treated by an experienced multimodality team 
    have a three-year disease-free survival of approximately 63%. 
    The impact of each component of multimodality therapy cannot 
    be determined, and improved survival may result, in addition, 
    from improved diagnostic and staging techniques currently 
    available.